DGX QUEST DIAGNOSTICS INC
Services-Medical Laboratories · NYSE · SEC CIK 1022079 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.1%
TTM net income YoY16.5%
TTM EPS YoY17.8%
Revenue 3-yr CAGR8.4%
Net income 3-yr CAGR14.0%
Margins
Gross margin33.1%
Operating margin14.6%
Net margin9.5%
FCF margin11.6%
EBITDA margin19.5%
Returns
ROE15.2%
ROA6.8%
ROIC (approx.)10.7%
Asset turnover0.71x
Leverage & solvency
Liabilities / assets53.4%
Debt / equity0.73x
Current ratio1.70x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.73x
Accruals ratio-4.9%
Payout ratio32.7%
Capex / revenue4.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $11.04B | $9.87B | $9.25B | $9.88B | $10.79B |
| Cost of revenue | $7.37B | $6.63B | $6.20B | $6.45B | $6.58B |
| Gross profit | $3.67B | $3.24B | $3.05B | $3.43B | $4.21B |
| SG&A expense | $1.97B | $1.77B | $1.64B | $1.87B | $1.73B |
| Operating income | $1.56B | $1.35B | $1.26B | $1.43B | $2.38B |
| Interest expense | — | — | $163.00M | $148.00M | $152.00M |
| Pretax income | $1.32B | $1.18B | $1.13B | $1.24B | $2.60B |
| Income tax | $314.00M | $273.00M | $248.00M | $264.00M | $597.00M |
| Net income | $992.00M | $871.00M | $854.00M | $946.00M | $2.00B |
| EBITDA | $2.13B | $1.84B | $1.70B | $1.86B | $2.79B |
| EPS (basic) | 8.87 | 7.78 | 7.59 | 8.10 | 15.85 |
| EPS (diluted) | 8.75 | 7.69 | 7.49 | 7.97 | 15.55 |
| Weighted avg. shares (diluted) | 113.00M | 113.00M | 113.00M | 118.00M | 128.00M |
| Banking | |||||
| Net interest income | -$264.00M | -$201.00M | -$152.00M | -$138.00M | -$151.00M |
| Balance sheet | |||||
| Cash & equivalents | $420.00M | $549.00M | $686.00M | $315.00M | $872.00M |
| Receivables | $1.41B | $1.30B | $1.21B | $1.20B | $1.44B |
| Inventory | $189.00M | $188.00M | $190.00M | $192.00M | $208.00M |
| Current assets | $2.38B | $2.39B | $2.37B | $1.90B | $2.74B |
| PP&E, net | $2.20B | $2.11B | $1.82B | $1.77B | $1.71B |
| Goodwill | $8.95B | $8.86B | $7.73B | $7.22B | $7.09B |
| Intangibles | $1.64B | $1.76B | $1.17B | $1.09B | $1.17B |
| Total assets | $16.23B | $16.15B | $14.02B | $12.84B | $13.61B |
| Current liabilities | $2.28B | $2.17B | $1.81B | $1.55B | $1.75B |
| Short-term debt | $504.00M | $602.00M | $303.00M | $2.00M | $2.00M |
| Long-term debt | $5.17B | $5.62B | $4.41B | $3.98B | $4.01B |
| Total debt | $5.67B | $6.22B | $4.71B | $3.98B | $4.01B |
| Total liabilities | $8.94B | $9.26B | $7.60B | $6.83B | $7.05B |
| Shareholders' equity | $7.17B | $6.78B | $6.31B | $5.89B | $6.44B |
| Net debt | $5.25B | $5.67B | $4.03B | $3.67B | $3.14B |
| Cash flow statement | |||||
| Operating cash flow | $1.89B | $1.33B | $1.27B | $1.72B | $2.23B |
| Capital expenditure | $527.00M | $425.00M | $408.00M | $404.00M | $403.00M |
| Free cash flow | $1.36B | $909.00M | $864.00M | $1.31B | $1.83B |
| Investing cash flow | -$631.00M | -$2.55B | -$1.06B | -$543.00M | $21.00M |
| Financing cash flow | -$1.39B | $1.08B | $160.00M | -$1.73B | -$2.54B |
| Depreciation & amortization | $570.00M | $493.00M | $439.00M | $437.00M | $408.00M |
| Stock-based compensation | $88.00M | $88.00M | $77.00M | $77.00M | $79.00M |
| Dividends paid | $353.00M | $331.00M | $314.00M | $305.00M | $309.00M |
| Share buybacks | $450.00M | $151.00M | $275.00M | $1.41B | $2.20B |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.